PRME
Prime Medicine, Inc.Company Information
- Company Name
- Prime Medicine, Inc.
- CIK
- CIK0001894562
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- PRME: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- PRME
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-01
- Last sale
- 2023-06-21
- Shares purchased (TTM)
- 10,919,900
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 100,901,196
- Shares outstanding
- 177,224,892
- Ownership
- 56.93%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 22.37%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | - | - | 115 | 92 | -4 | 48 | 3 | -50 | -7 | 110 | 75 | 36 | ||||||
| Related Party | - | - | 115 | 92 | -4 | 48 | 3 | -50 | -7 | 110 | 75 | 36 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 47 | 64 | 63 | 71 | 54 | 92 | 182 | 118 | 56 | 94 | 42 | 44 | ||||||
| Prepaid Expense And Other Assets Current | - | - | - | - | - | - | - | - | - | - | - | 19 | ||||||
| Accounts Receivable Gross Current | - | - | - | - | 0 | 0 | - | 55 | - | - | - | - | ||||||
| Available For Sale Securities Debt Securities Current | 48 | 71 | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 1 | 2 | 3 | 2 | 3 | 3 | 7 | 6 | 4 | 4 | 19 | - | ||||||
| Other Assets Current | 0 | 0 | 1 | 16 | 16 | 17 | 15 | 10 | 4 | 3 | 2 | - | ||||||
| Assets Current | 97 | 138 | 181 | 231 | 121 | 164 | 212 | 246 | 171 | 218 | 143 | 185 | ||||||
| Property Plant And Equipment Net | 17 | 19 | 21 | 22 | 24 | 25 | 24 | 23 | 24 | 24 | 23 | 22 | ||||||
| Operating Lease Right Of Use Asset | 120 | 123 | 126 | 118 | 120 | 125 | 47 | 49 | 52 | 56 | 14 | 17 | ||||||
| Restricted Cash Noncurrent | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 13 | 13 | 13 | 13 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | - | - | - | 0 | 0 | 0 | 1 | 1 | 2 | ||||||
| Assets | 249 | 295 | 343 | 385 | 279 | 328 | 298 | 333 | 260 | 311 | 194 | 239 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 6 | 12 | 9 | 9 | 6 | 10 | 11 | 5 | 5 | 10 | 20 | 14 | ||||||
| Accrued Liabilities Current | 9 | 8 | 13 | 11 | 12 | 9 | 16 | 19 | 11 | 8 | 14 | 14 | ||||||
| Contract With Customer Liability Current | 8 | 7 | 8 | 7 | 8 | 8 | 7 | 9 | - | - | 0 | - | ||||||
| Operating Lease Liability Current | 9 | 9 | 8 | 8 | 7 | 7 | 4 | 4 | 5 | 7 | 9 | 11 | ||||||
| Liabilities Current | 32 | 36 | 37 | 35 | 34 | 34 | 38 | 38 | 21 | 24 | 56 | 39 | ||||||
| Contract With Customer Liability Noncurrent | 56 | 58 | 58 | 60 | 60 | 61 | 63 | 63 | - | - | 0 | - | ||||||
| Operating Lease Liability Noncurrent | 104 | 106 | 108 | 110 | 112 | 114 | 37 | 37 | 36 | 37 | 4 | 6 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities | 209 | 218 | 222 | 223 | 218 | 221 | 144 | 143 | 63 | 68 | 61 | 45 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,019 | 1,014 | 1,009 | 1,004 | 853 | 846 | 840 | 834 | 789 | 781 | 624 | 620 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -980 | -937 | -888 | -842 | -792 | -739 | -687 | -645 | -592 | -537 | -491 | -426 | ||||||
| Stockholders Equity | 40 | 77 | 121 | 162 | 61 | 107 | 153 | 190 | 197 | 244 | 133 | 194 | ||||||
| Liabilities And Stockholders Equity | 249 | 295 | 343 | 385 | 279 | 328 | 298 | 333 | 260 | 311 | 194 | 239 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 775 | 775 | 775 | 775 | 775 | 775 | 775 | 775 | 775 | 775 | 775 | 775 | ||||||
| Common Stock Shares Issued | 181 | 181 | 181 | 180 | 134 | 131 | 131 | 131 | 120 | 120 | 97 | 97 | ||||||
| Shares Outstanding | 181 | 181 | 181 | 180 | 134 | 131 | 131 | 131 | 120 | 120 | 97 | 97 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPrime Medicine, Inc. (PRME) — SEC Financial Statements & Analysis
Prime Medicine, Inc. (PRME) is a biological products, (no diagnostic substances) company, incorporated in DE. Prime Medicine, Inc. trades on Nasdaq as: PRME. Prime Medicine, Inc. (PRME)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Prime Medicine, Inc. carries a market cap of $653.96M, a P/E ratio of -3.48x, a P/B ratio of 16.43x, a P/S ratio of 160.56x, an enterprise value of $606.51M, and an EV/EBITDA multiple of -3.21x. On profitability, it posts an operating margin of -4824.94%, a net margin of -4613.11%, a Return on Equity (ROE) of -373.29%, a Return on Assets (ROA) of -71.16%, and a Return on Invested Capital (ROIC) of -1486.49%. Per share, it reports EPS of $-1.06, diluted EPS of $-1.06, free cash flow per share of $-0.89, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -17.90% year-over-year, net income growth of -5.71% year-over-year, and EPS growth of -31.27% year-over-year. On the balance sheet, it maintains a current ratio of 3.05x, a quick ratio of 3.01x, working capital of $65.11M, a debt-to-equity ratio of 5.26x, a debt ratio of 0.84, free cash flow of $-156.85M (TTM), and net debt of $-47.45M. Figures sourced from SEC EDGAR.
- Market Cap
- $653.96M
- P/E TTM
- -3.48x
- EPS TTM
- $-1.06
- P/B TTM
- 16.43x
- ROE TTM
- -373.29%
- ROA TTM
- -71.16%
- Debt To Equity
- 5.26x
- Free Cash Flow TTM
- $-156.85M
- Net Revenue TTM Growth 1Y
- -17.90%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Prime Medicine, Inc. in?
Prime Medicine, Inc. (PRME) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does PRME trade on?
Prime Medicine, Inc. (PRME) trades on the Nasdaq.
Where is Prime Medicine, Inc. incorporated?
Prime Medicine, Inc. is incorporated in DE.
When was Prime Medicine, Inc. (PRME)'s most recent SEC filing?
Prime Medicine, Inc. (PRME)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is PRME's market cap?
Prime Medicine, Inc. (PRME) has a market capitalization of $653.96M as of 2026-06-30.
What is PRME's EPS (earnings per share)?
Prime Medicine, Inc. (PRME)'s trailing twelve month EPS is $-1.06 as of 2026-06-30.
What is PRME's ROE (return on equity)?
Prime Medicine, Inc. (PRME)'s trailing twelve month Return on Equity (ROE) is -373.29% as of 2026-06-30.
What is PRME's ROA (return on assets)?
Prime Medicine, Inc. (PRME)'s trailing twelve month Return on Assets (ROA) is -71.16% as of 2026-06-30.
What is PRME's ROIC (return on invested capital)?
Prime Medicine, Inc. (PRME)'s trailing twelve month Return on Invested Capital (ROIC) is -1486.49% as of 2026-03-31.
What is PRME's EV/EBITDA?
Prime Medicine, Inc. (PRME)'s trailing twelve month EV/EBITDA is -3.21x as of 2026-06-30.